Prognostic Value of N-Terminal Pro-Brain Natriuretic Peptide and High-Sensitivity Troponin T Levels in the Natural History of Transthyretin Amyloid Cardiomyopathy and Their Evolution after Tafamidis Treatment

Oghina, Silvia; Josse, Constant; Bézard, Mélanie; Kharoubi, Mounira; Delbarre, M.A.; Eyharts, Damien; Zaroui, Amira; Guendouz, Soulef; Galat, Arnault; Hittinger, Luc; Fanen, Pascale; Teíger, Emmanuel; Mouri, Nadir; Montestruc, François; Damy, Thibaud

doi:10.3390/jcm10214868

Cited by 16 publications

(9 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, natriuretic peptides are elevated also in other conditions, such as ischaemic heart disease and pulmonary embolism, not being a specific HF biomarker [71,72]. Baseline high sensitivity cardiac troponin T and its increase are associated with mortality, disease worsening and acute decompensation, in HF patients [72][73][74][75][76][77][78][79]. Sensitive contemporary cardiac troponin I is also a predictive biomarker of all-cause and cardiovascular mortality, in HF outpatients [73].…”

Section: Heart Failure Pathophysiology Paradigm: What Is Beyond Left ...mentioning

confidence: 99%

Do the Current Guidelines for Heart Failure Diagnosis and Treatment Fit with Clinical Complexity?

Severino

D’Amato

Prosperi

et al. 2022

JCM

View full text Add to dashboard Cite

Heart failure (HF) is a clinical syndrome defined by specific symptoms and signs due to structural and/or functional heart abnormalities, which lead to inadequate cardiac output and/or increased intraventricular filling pressure. Importantly, HF becomes progressively a multisystemic disease. However, in August 2021, the European Society of Cardiology published the new Guidelines for the diagnosis and treatment of acute and chronic HF, according to which the left ventricular ejection fraction (LVEF) continues to represent the pivotal parameter for HF patients’ evaluation, risk stratification and therapeutic management despite its limitations are well known. Indeed, HF has a complex pathophysiology because it first involves the heart, progressively becoming a multisystemic disease, leading to multiorgan failure and death. In these terms, HF is comparable to cancer. As for cancer, surviving, morbidity and hospitalisation are related not only to the primary neoplastic mass but mainly to the metastatic involvement. In HF, multiorgan involvement has a great impact on prognosis, and multiorgan protective therapies are equally important as conventional cardioprotective therapies. In the light of these considerations, a revision of the HF concept is needed, starting from its definition up to its therapy, to overcome the old and simplistic HF perspective.

show abstract

Section: Heart Failure Pathophysiology Paradigm: What Is Beyond Left ...mentioning

confidence: 99%

Do the Current Guidelines for Heart Failure Diagnosis and Treatment Fit with Clinical Complexity?

Severino

D’Amato

Prosperi

et al. 2022

JCM

View full text Add to dashboard Cite

show abstract

“…A clinical benefit of tafamidis treatment, in terms of prolonged major cardiovascular outcome-free survival, lower deterioration of structural and functional changes of the left ventricle, and myocardial work, was also reported outside the frame of clinical trials, in retrospective series of real-life patients [119][120][121][122].…”

Section: Tafamidismentioning

confidence: 80%

Oral Therapy for the Treatment of Transthyretin-Related Amyloid Cardiomyopathy

Girelli

Merlini

2022

IJMS

View full text Add to dashboard Cite

The care of systemic amyloidosis has improved dramatically due to improved awareness, accurate diagnostic tools, the development of powerful prognostic and companion biomarkers, and a continuous flow of innovative drugs, which translated into the blooming of phase 2/3 interventional studies for light chain (AL) and transthyretin (ATTR) amyloidosis. The unprecedented availability of effective drugs ignited great interest across various medical specialties, particularly among cardiologists who are now recognizing cardiac amyloidosis at an extraordinary pace. In all amyloidosis referral centers, we are observing a substantial increase in the prevalence of wild-type transthyretin (ATTRwt) cardiomyopathy, which is now becoming the most common form of cardiac amyloidosis. This review focuses on the oral drugs that have been recently introduced for the treatment of ATTR cardiac amyloidosis, for their ease of use in the clinic. They include both old repurposed drugs or fit-for-purpose designed compounds which bind and stabilize the TTR tetramer, thus reducing the formation of new amyloid fibrils, such as tafamidis, diflunisal, and acoramidis, as well as fibril disruptors which have the potential to promote the clearance of amyloid deposits, such as doxycycline. The development of novel therapies is based on the advances in the understanding of the molecular events underlying amyloid cardiomyopathy.

show abstract

“…Cardiac troponin T is known as one of the most sensitive biomarkers for myocardial injury (25). Recently, several studies have demonstrated that high levels of NT-proBNP and cardiac troponin T had a strong predictive ability for CA diagnosis and prognosis prediction (26,27). In our study, both elevated NT-proBNP and cardiac troponin T were found in patients with definite and possible CA, which showed a slightly better diagnostic value compared to native T1 and comparable value with ECV, further supporting the equivalent role of native T1 and ECV as diagnosis indexes.…”

Section: Discussionmentioning

confidence: 99%

3.0T cardiac magnetic resonance quantification of native T1 and myocardial extracellular volume for the diagnosis of late gadolinium enhancement-negative cardiac amyloidosis

Liu¹,

Zhu²,

Chen³

et al. 2022

Ann Transl Med

View full text Add to dashboard Cite

Background: Late gadolinium enhancement (LGE) by cardiac magnetic resonance (CMR) is useful for the detection of cardiac amyloidosis (CA), but characteristic LGE patterns do not always occur or they appear late in the disease. Native T1 and extracellular volume (ECV) by T1 mapping may improve disease detection and quantify myocardial amyloid load.Methods: Thirty patients with definite CA, 10 patients with possible CA, 20 patients with hypertrophic cardiomyopathy (HCM) and 40 healthy volunteers were performed 3.0-T CMR including cine, pre-and postcontrast T1 mapping and LGE. Receiver-operating characteristic (ROC) curves were constructed to assess the diagnostic ability of native T1 and ECV for CA. Correlation analysis between native T1 or ECV and cardiac biomarkers, structure, and function indexes were assessed using Pearson or Spearman correlation, as appropriate.

show abstract

Prognostic Value of N-Terminal Pro-Brain Natriuretic Peptide and High-Sensitivity Troponin T Levels in the Natural History of Transthyretin Amyloid Cardiomyopathy and Their Evolution after Tafamidis Treatment

Cited by 16 publications

References 26 publications

Do the Current Guidelines for Heart Failure Diagnosis and Treatment Fit with Clinical Complexity?

Do the Current Guidelines for Heart Failure Diagnosis and Treatment Fit with Clinical Complexity?

Oral Therapy for the Treatment of Transthyretin-Related Amyloid Cardiomyopathy

3.0T cardiac magnetic resonance quantification of native T1 and myocardial extracellular volume for the diagnosis of late gadolinium enhancement-negative cardiac amyloidosis

Contact Info

Product

Resources

About